Quick Answer
VYNE Therapeutics Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
VYNE Therapeutics Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2021 | $0.00 | -100.0% |
| 2020 | $33.17M | +1.4% |
| 2019 | $32.73M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2021 | $0.00 | -100.0% | — |
| June 30, 2021 | $0.00 | -100.0% | -100.0% |
| March 31, 2021 | $33.27M | +1.4% | +0.3% |
| December 31, 2020 | $33.17M | +1.4% | +0.5% |
| September 30, 2020 | $33.02M | — | +0.3% |
| June 30, 2020 | $32.91M | — | +0.3% |
| March 31, 2020 | $32.82M | — | +0.3% |
| December 31, 2019 | $32.73M | — | — |
- VYNE Therapeutics Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2021 period, VYNE Therapeutics Inc.’s long-term debt has declined by 100.0% (from $32.73 million to $0.00).
- The most recent figure is from VYNE Therapeutics Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 17, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: